Zhongsheng Pharmaceutical (002317.SZ) subsidiary obtained ethical approval for Phase III clinical trial of innovative drug Angla Diwei Granules.

China Finance and Economics App News, Zhongsheng Pharmaceutical (002317.SZ) announced that recently, the company's controlling subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. (hereinafter referred to as "Zhongsheng Ruichuang"), has received approval from the Clinical Research Project Review Committee of Capital Medical University Affiliated Beijing Children's Hospital to conduct a multicenter, randomized, double-blind, positive-controlled phase III clinical trial on the safety and efficacy of the innovative drug Anglatavir Granules in children aged 2-11 with uncomplicated influenza A.